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This update of the Cartwright blood group system (George MR. 
Cartwright blood group system review. Immunohematology 
2012;28:49–54) reports the addition of three new antigens. From 
1956 until 2017, the Cartwright (Yt) blood group system consisted 
of two antigens, Yta and Ytb. Yta is a high-prevalence antigen, and 
its antithetical antigen, Ytb, shows much lower prevalence. In 
2017, YTEG was identified, and, in 2018, the International Society 
of Blood Transfusion added high-prevalence antigens YTLI and 
YTOT. Cartwright antigens result from point mutations in the 
acetylcholinesterase gene on chromosome 7q. Little is known about 
antibodies against YTEG, YTLI, and YTOT. Discovery of these 
new antigens required plasma inhibition studies and molecular 
analysis for further characterization. Based on experience with 
Yta and Ytb, Cartwright antibodies have rarely demonstrated 
clinical significance; nevertheless, cases of in vivo hemolysis 
have been reported, suggesting that clinical significance should 
be interpreted on a case-by-case basis. Immunohematology 
2019;35:154–155.
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Molecular Update
Historically, the majority of molecular methods used 
in red blood cell (RBC) antigen testing used specific single 
nucleotide polymorphisms or single nucleotide variants. These 
methods can only detect a limited selection of known alleles. 
This limitation can result in missing new or uncommon 
alleles and can subsequently lead to incorrect interpretation of 
phenotypes. Next generation sequencing (NGS) methods do 
not have this limitation and appear to be better suited to detect 
novel polymorphisms.1 Scharberg et al.2 demonstrated the 
use of genotyped RBCs in antibody identification in a study of 
nearly 17,000 blood samples from close to 8500 patients tested 
in their reference lab. In this 3-year study, 21 antibodies from 
10 blood group systems were identified in 126 patients by using 
the genotype information of these reagent RBCs. Antibodies 
to Cartwright antigens were among the most frequent, 
accounting for antibodies identified in 31 patients (25%). 
This study suggests that genotyping may extend the range 
of detectable specificities to expedite antibody identification. 
Indeed, the use of NGS sequencing was instrumental in the 
identification of YTEG as being a homozygous mutation 
c.266G>A in exon 2, which resulted in an amino acid change 
p.Gly89Glu in acetylcholinesterase (AChE).3,4 YT4 (or YTLI) 
was found through a complex antibody workup in a pregnant 
woman with anti-Jka. The patient’s RBCs typed Yt(a+b–), 
YTEG+, and molecular ACHE sequencing analysis confirmed 
a novel homozygous mutation c.169G>A in exon 2, encoding 
p.Gly57Arg change in AChE. This sequence was found in 
both the patient and her crossmatch-compatible brother.5 The 
most recent addition to the YT system, YT5 (or YTOT), was 
discovered in the workup of a pregnant woman with sickle cell 
disease. She had multiple RBC antibodies and an unknown 
specificity inhibited by soluble recombinant Yt antigen (srYt). 
Antibodies to other Yt antigens (Yta, YTEG, and YTLI) were 
excluded, although ACHE sequence analysis revealed a 
novel homozygous mutation c.101G>A in exon 2, encoding 
p.Arg34Gln change in AChE.5 Given the recent discovery of 
the three new YT antigens (YTEG, YTLI, and YTOT), too 
little is known about their genetics/inheritance, other than 
to note that these three antigens are all of high prevalence.3–5 
The molecular basis of the Yt antigens can be summarized in 
Table 1.3–8
Biochemistry Update
Of note, Cartwright antigens are sensitive to dithiothreitol 
(DTT) treatment used to negate interference of daratumumab 
(DARA), an IgG1k monoclonal antibody against CD38 on 
plasma cells in plasma cell myeloma. This finding lends further 
support for RBC antigen phenotyping or genotyping before the 
patient is treated with DARA, because Cartwright antibodies, 
along with several others, could be missed in the DTT test 
environment.9 Inhibition studies using srYt were instrumental 
in further characterizing the three new Yt antigens discovered 
in recent years—YTEG, YTLI, and YTOT.
Nomenclature
The first two antigens, Yta and Ytb, were named after the 
patient, Mrs. Cartwright, in whom the antibody was first 
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identified; the third antigen, YTEG, was named after the 
proband; and the fourth and fifth, YTLI and YTOT, were 
named after the referring laboratories. The nomenclature 
across various systems is denoted in Table 2.3–6
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Table 1. Molecular basis of the Yt antigens
Yta Ytb YTEG YTLI YTOT
Amino acid His 353 Asn 353 p.Gly89Glu p.Gly57Arg p.Arg34Gln

















Nucleotide at position 1431C>T 
in exon 3 also differentiates Yta 
from Ytb but does not alter the 
encoded amino acid. A second 
silent mutation in exon 5 does not 
correlate with the Yt polymorphism.
Nucleotide at position 1431C>T in 
exon 3 also differentiates Yta from 
Ytb but does not alter the amino 
acid. A second silent mutation in 
exon 5 does not correlate with the 
Yt polymorphism.
Table 2. Nomenclature for the Yt blood group system
System name System symbol Gene symbol
Traditional/ISBT ISBT number Traditional ISBT ISBT number Traditional ISBT ISGN






ISBT = International Society of Blood Transfusion; ISGN = International System for Gene Nomenclature.
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